Free Republic
Browse · Search
News/Activism
Topics · Post Article

Skip to comments.

FDA to review "missing" drug company documents (Prozac + AK-47 + workplace, guess what?)
The British Medical Journal ^ | 1 January 2005 | Jeanne Lenzer

Posted on 12/30/2004 10:16:24 PM PST by neverdem

BMJ


Home Help Search Archive Feedback

Table of Contents

[Advanced]


BMJ  2005;330:7 (1 January), doi:10.1136/bmj.330.7481.7

Extract of this article

PDF of this article

Email this article to a friend

Respond to this article

Download to Citation Manager

Search Medline for articles by:

Lenzer, J.

Alert me when:

New articles cite this article

News

FDA to review "missing" drug company documents

Jeanne Lenzer

New York

The US Food and Drug Administration has agreed to review confidential drug company documents that went missing during a controversial product liability suit more than 10 years ago. The documents appear to suggest a link between the drug fluoxetine (Prozac), made by Eli Lilly, and suicide attempts and violence.

The missing documents, which were sent to the BMJ by an anonymous source last month, include reviews and memos indicating that Eli Lilly officials were aware in the 1980s that fluoxetine had troubling side effects and sought to minimise their likely negative effect on prescribing.

The documents received by the BMJ reportedly went missing during the 1994 Wesbecker case that grew out of a lawsuit filed on behalf of victims of a work-place shooting in 1989. Joseph Wesbecker, armed with an AK-47, shot eight people dead and wounded another 12. He then shot and killed himself. Mr Wesbecker, who had a long history of depression, had been placed on fluoxetine one month before the shootings.

One of the internal company documents, a report of 8 November 1988, entitled "Activation and Sedation in Fluoxetine Clinical Trials," found that in clinical trials "38% of fluoxetine-treated patients reported new activation but 19% of placebo-treated patients also reported new activation yielding a difference of 19% attributable to fluoxetine."

The FDA recently issued a warning that antidepressants can cause a cluster of "activating" or stimulating symptoms such as agitation, panic attacks, insomnia, and aggressiveness. Dr Joseph Glenmullen, a Harvard psychiatrist and author of The Antidepressant Solution, published by Free Press, said it should come as little surprise that fluoxetine might cause serious behavioural disturbances, as it is similar to cocaine in its effects on serotonin.

Dr Richard Kapit, the FDA clinical reviewer who approved fluoxetine, said he was not given the Lilly data. "These data are very important. If this report was done by Lilly or for Lilly, it was their responsibility to report it to us and to publish it."

Congressman Maurice Hinchey's office is currently reviewing the documents to determine whether Lilly withheld data from the public and the FDA. Mr Hinchey (Democrat, New York) said: "This is an alarming study that should have been shared with the public and the FDA from the get-go, not 16 years later.

"This case demonstrates the need for Congress to mandate the complete disclosure of all clinical studies for FDA-approved drugs so that patients and their doctors, not the drug companies, decide whether the benefits of taking a certain medicine outweigh the risks."

The plaintiffs in the Wesbecker product liability sought to show that Eli Lilly withheld negative study data from the FDA and that fluoxetine tipped Wesbecker over into a homicidal rage. Lilly won a 9 to 3 jury verdict in late 1994 and subsequently claimed that it was "proven in a court of law... that Prozac is safe and effective."

The trial judge, Justice John Potter, suspecting that a secret deal had been struck, pursued Lilly and the plaintiffs, eventually forcing Lilly in 1997 to admit that it had made a secret settlement with the plaintiffs during the trial. Infuriated by Lilly's actions, Judge Potter ordered the finding changed from a verdict in Lilly's favour to one of "dismissed as settled with prejudice," saying, "Lilly sought to buy not just the verdict but the court's judgment as well."

David Graham, currently associate director in the FDA's Office of Drug Safety, criticised the analysis of post-marketing surveillance data submitted by Lilly to the FDA. After discovering that Lilly failed to obtain systematic assessments of violence and had excluded 76 of 97 cases of reported suicidality, Dr Graham concluded in a memo dated 11 September 1990 that "because of apparent large-scale underreporting, [Lilly's] analysis cannot be considered as proving that fluoxetine and violent behavior are unrelated."


Congressman Maurice Hinchey said that the internal Lilly data "should have been shared with the public"

Credit: CONGRESSMAN MAURICE HINCHEY

An FDA advisory panel was convened in 1991 to review the fluoxetine data. It concluded that fluoxetine was safe despite the concerns raised by Dr Graham and others, leading critics to point out that several of the panellists had financial ties to Eli Lilly.

Dr Glenmullen said the missing documents obtained by the BMJ provide "the missing link" between the recent advisory issued by the FDA and what Lilly scientists knew 16 years ago.

Since the 1991 FDA hearings Dr Peter Breggin, who served as the medical expert in the Wesbecker case, has warned that the stimulant effects of fluoxetine can cause suicide and violence. He cautions that the 38% activation rate reported in the missing document is probably low because "it doesn't include other symptoms of activation such as panic attacks, hypomania, and mania."

Dr Kapit, the original reviewer for fluoxetine, told the BMJ, "If we have good evidence that we were misled and data were withheld then I would change my mind [about the safety of fluoxetine]. I do agree now that these stimulatory side effects, especially in regards to suicidal ideation and homicidal ideation, are worse than I thought at the time that I reviewed the drug."

Lilly declined to be interviewed but issued a written statement saying, "Prozac has helped to significantly improve millions of lives. It is one of the most studied drugs in the history of medicine, and has been prescribed for more than 50 million people worldwide. The safety and efficacy of Prozac is well studied, well documented, and well established."





Extract of this article

PDF of this article

Email this article to a friend

Respond to this article

Download to Citation Manager

Search Medline for articles by:

Lenzer, J.

Alert me when:

New articles cite this article



Home Help Search Archive Feedback

Table of Contents

BMJ

The general medical journal website.


© 2004 BMJ Publishing Group Ltd


TOPICS: Business/Economy; Crime/Corruption; Culture/Society; Front Page News; Government; News/Current Events; Technical; US: District of Columbia; US: Indiana; United Kingdom
KEYWORDS: banglist; breggin; cchrscientology; churchofscientology; cult; elililly; fda; fluoxetine; mentalhealth; prozac; scientologist; scientology; ssri
Navigation: use the links below to view more comments.
first previous 1-2021-24 last
To: neverdem
Okay Neverdem I want to get off this thread. I can't change your perception but I do want to leave you with this thought.

Many news articles that you have read and will continue to read which include adverse information about psychotropic medication are very likely based in whole or in part on daily press releases from the Church of Scientology or its sub-groups such as CCHR and others.

It is extremely difficult for most to discern from a simple news article the level of Scientology slant.

Many people can't detect that a news article has been tainted by a lazy reporter relying on so-called fact sheets and press releases which were written and published by Scientology's "medical experts" and cultees.

The quoted so-called "medical experts" are likely to be Scientologists and Scientology CCHR Board Members Dr. Mary Ann Block, D.O., Dr. Peter Breggin and others writing the releases according to Church of Scientology principles, not according to scientific research.

Enough. :)

I wish you well.

21 posted on 12/31/2004 11:07:42 AM PST by bd476
[ Post Reply | Private Reply | To 19 | View Replies]

To: neverdem; bd476
There are distinct abnormalities in the ADD/ADHD brain that are also commonly related to depression. If the abnormalities are sufficiently large, stimulation may be necessary to overcome the natural lack of abilities. See below:

Nov. 20, 2003 — Anatomical abnormalities associated with attention deficit–hyperactivity disorder (ADHD) can be visualized on high-resolution magnetic resonance imaging (MRI), according to the results of a study published in the Nov. 22 issue of The Lancet.

"Our morphometric procedures allow more precise localization of group differences than do the methods used in previous studies," lead author Elizabeth R. Sowell, PhD, from the University of California at Los Angeles, says in a news release. "Our results therefore suggest that the disturbances in prefrontal cortices are localized to more inferior aspects of prefrontal regions than was previously appreciated. Our findings also indicate that prefrontal abnormalities are represented bilaterally, by contrast to the predominantly right-sided findings that were emphasized in other reports."

Of 27 children and adolescents with ADHD evaluated in this study, 11 were girls and 16 were boys. Compared with 46 controls without ADHD who were matched for age and sex, those with ADHD had reduced regional brain size localized predominantly to small areas of the dorsal prefrontal cortices, as well as in bilateral anterior temporal areas. The ADHD group also had significant increases in the gray matter in large regions of the posterior temporal and inferior parietal cortices.

"The findings are not only in brain regions controlling attention, but also in regions that subserve impulse control," says coauthor Bradley Peterson, MD, from Columbia University and the New York State Psychiatric Institute in New York City. "Disordered impulse control is often the most clinically debilitating symptom in children with ADHD."

Although measures of the severity of ADHD symptom subtypes generally did not correlate significantly with these morphological measures, gray matter in the occipital lobe was inversely correlated with measures of inattention.

Study limitations include small sample size precluding subtyping by anatomical abnormalities and possible confounding by stimulant drugs, which were used by 15 of the 27 patients.

"These findings may help us understand the sites of action of the medications used to treat ADHD, particularly stimulant medications," Dr. Peterson says. "In conjunction with other imaging techniques, the findings may help us to develop new therapeutic agents given our knowledge of the cellular and neurochemical make-up of brain regions where we detected the greatest abnormalities."

The National Institutes of Mental Health and the Suzanne Crosby Murphy Endowment at Columbia University helped support this study. The authors report no financial conflicts of interest.

Lancet. 2003;362:1699-1707

Reviewed by Gary D. Vogin, MD
22 posted on 12/31/2004 12:20:23 PM PST by IncredibleHulk (Courage is the Price that Life extracts for granting Peace. –Anne Morrow Lindberg)
[ Post Reply | Private Reply | To 20 | View Replies]

To: IncredibleHulk

Thanks for posting the article. They need a much larger sample of patients, divided into ADD and ADHD, who haven't been started on stimulants, and controls to see if these anatomical differences are real.


23 posted on 12/31/2004 1:06:02 PM PST by neverdem (May you be in heaven a half hour before the devil knows that you're dead.)
[ Post Reply | Private Reply | To 22 | View Replies]

To: Petronski

Maybe so. It was complete hell, and physicians who tell patients to "tough it out" or dismiss physical reactions all together don't help.


24 posted on 12/31/2004 4:59:30 PM PST by Canticle_of_Deborah
[ Post Reply | Private Reply | To 10 | View Replies]


Navigation: use the links below to view more comments.
first previous 1-2021-24 last

Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.

Free Republic
Browse · Search
News/Activism
Topics · Post Article

FreeRepublic, LLC, PO BOX 9771, FRESNO, CA 93794
FreeRepublic.com is powered by software copyright 2000-2008 John Robinson